Dr Russell Howard
On behalf of the Board, I welcome you to Immutep’s Annual General Meeting for 2018.
I am pleased to address you for the first time as Chairman of your company, after taking on the role from Lucy Turnbull. This is also our first AGM as Immutep, having received shareholder approval for our name change this time last year.
The name Immutep has resonated well with our industry stakeholders. It has helped to strengthen our association and focus on Lymphocyte-activation gene 3 (LAG-3), discovered by Dr Triebel. As Immutep, with our deep LAG-3 expertise and patent estate, we will continue working hard to advance potential therapies for patients with cancer and autoimmune disease.
For further information please download PDF attached:
Download this document
